Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 5Ovarian Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Neoplasms 3Stomach Neoplasms 2Retinoblastoma 2Neoplasms 2Uterine Cervical Neoplasms 1Squamous-Cell Lung Cancer 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1NSCLC 1Lymphatic Metastasis 1Liver Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Bronchogenic 1Carcinoma 1

Interventions

Indocyanine Green 7Surgical Procedures, Operative 5Lymph Node Excision 5Radiotherapy, Intensity-Modulated 4Radiotherapy 4Radiosurgery 4Cisplatin 4gadofosveset trisodium 2TP protocol 2Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Magnetic Resonance Spectroscopy 2Electroporation 2Conversion to Open Surgery 2Control Groups 2Chemotherapy, Adjuvant 2Chemoradiotherapy 2Artificial Intelligence 2tislelizumab 1sarcolipin 1lncRNA LNMAT1, human 1gewf solution 1fluoroazomycin arabinoside 1X-Rays 1Technetium-99 1Technetium 1Surgery, Computer-Assisted 1Spectrum Analysis 1Specimen Handling 1Robotic Surgical Procedures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphatic Metastasis × Platinum Compounds × Clear all
NCT07538193 2026-04-20

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer

Tang-Du Hospital

Phase NA Not yet recruiting
28 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡